Probi AB (publ) (STO: PROB)

Market Cap	3.17B
Revenue (ttm)	642.71M
Net Income (ttm)	13.70M
Shares Out	11.39M
EPS (ttm)	1.20
PE Ratio	231.18
Forward PE	149.06
Dividend	1.30 (0.47%)
Ex-Dividend Date	May 8, 2024

Volume	205
Open	264.00
Previous Close	280.00
Day's Range	264.00 - 279.00
52-Week Range	171.50 - 319.00
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 22, 2024

About Probi AB

Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally. The company conducts research primarily in the fields of mental, digestive, immune, bone, oral, children’s, women’s, and senior health, as well as iron absorption. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beve...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 162
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PROB

Financial Performance

In 2023, Probi AB's revenue was 627.69 million, an increase of 1.52% compared to the previous year's 618.29 million. Earnings were 16.82 million, a decrease of -58.60%.